Last reviewed · How we verify

Osteoporosis — Treatment Landscape & Competitive Intelligence

Osteoporosis (Metabolic & Endocrinology) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Metabolic & Endocrinology 10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Osteoporosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Tymlos ABALOPARATIDE Radius Parathyroid Hormone-Related Peptide Analog [EPC] Parathyroid hormone/parathyroid hormone-related peptide receptor 2017-01-01
Prolia DENOSUMAB Amgen RANK Ligand Inhibitor [EPC] Tumor necrosis factor ligand superfamily member 11 2010-01-01
Zometa ZOLEDRONIC ACID Novartis zoledronic acid Farnesyl pyrophosphate synthase 2001-01-01
Infuvite Adult Colecalciferol Novartis Vitamin D Vitamin D3 receptor 2000-01-01
Prepopik MAGNESIUM OXIDE Baxter magnesium oxide 1982-01-01
Drisdol ERGOCALCIFEROL Esjay Pharma Provitamin D2 Compound [EPC] 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial 1941-01-01
Minodronate Minodronate Peking University Third Hospital Geranylgeranyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl diphosphate synthase
ELDECALCITOL ELDECALCITOL Chugai Pharmaceutical Co., Ltd Vitamin D3 receptor
Bisphonal INCADRONIC ACID Astellas Pharma incadronic acid Farnesyl pyrophosphate synthase
Zometa Zometa University of Arkansas Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 8 drugs in Osteoporosis
  2. Novartis · 2 drugs in Osteoporosis
  3. Astellas Pharma · 1 drug in Osteoporosis
  4. Baxter · 1 drug in Osteoporosis
  5. Children's Hospital Medical Center, Cincinnati · 1 drug in Osteoporosis
  6. Chugai Pharmaceutical Co., Ltd · 1 drug in Osteoporosis
  7. Department of Medical Services Ministry of Public Health of Thailand · 1 drug in Osteoporosis
  8. Ente Ospedaliero Ospedali Galliera · 1 drug in Osteoporosis
  9. Esjay Pharma · 1 drug in Osteoporosis
  10. Guy's and St Thomas' NHS Foundation Trust · 1 drug in Osteoporosis
  11. Instituto Mexicano del Seguro Social · 1 drug in Osteoporosis
  12. Peking University Third Hospital · 1 drug in Osteoporosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Osteoporosis:

Cite this brief

Drug Landscape (2026). Osteoporosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/osteoporosis. Accessed 2026-05-15.

Related